Pharmacokinetics & Drug Delivery | Antimicrobial Agents | Invasive Fungal Infections | Bacterial Infections | Methods for Diagnostic & Therapeutic Studies
Anidulafungin pharmacokinetics in critically ill patients
MJP van Wanrooy, MMG Rodgers, DRA Uges, JP Arends, JG Zijlstra, TS van der Werf, JGW Kosterink, JWC Alffenaar*
*Corresponding author: JWC Alffenaar
Clinical Pharmacology, University Medical Center Groningen (UMCG), Groningen, Netherlands
F1000Posters 2012, 3: 318 (poster) [English]
Poster [206.96 KB]
Presented at
22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2012,
30 Mar - 2 Apr 2012, P000
Early antifungal treatment with adequate drug exposure reduces mortality in patients with candidemia. Efficacy of anidulafungin is driven by the AUC (area under the curve)/MIC ratio. As anidulafungin clearance is approximately 30% higher in patients with invasive candidiasis than in patients with oesophageal candidiasis, patients at the ICU may be at risk of underexposure. Therefore, insight in anidulafungin pharmacokinetics in a ‘real-life’ population of critically ill patients is important.
1) Anidulafungin exposure in our critically ill patients seems lower compared to earlier data. Further analysis is required to determine the factors causing the apparent difference. The effect on outcome has to be evaluated in a prospective study.
2) Trough concentrations correlated very well with total anidulafungin exposure.
We propose to use trough concentrations as a surrogate for AUC in therapeutic drug monitoring as this is much easier and practicable in routine practice.
No relevant competing interests disclosed.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
